Latest Breaking News On - Maintenance recurrent ovarian - Page 1 : comparemela.com

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

First Phase 3 survival data from KEYNOTE-A39/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for.

United statesSeagen padcevSeagen incEuropean society for medical oncologyAgensys incMerck research laboratoriesMerck co incExchange commissionStatement of merck co incEuropean societyMedical oncologyMarjorie greenMerck researchOncology investor eventProffered paperBacillus calmette guerin unresponsive

AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients

AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesPuerto ricoBrendan mcevoyDave fredricksonJournal of the american medical associationInflation reduction actOrphan drug actExecutive vice presidentOncology business unitAmerican medical associationNetwork openParoxysmal nocturnal hemoglobinuriaPatient safety cardPrescribing informationMedication guide

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJulie cunninghamMototsugu oyaChrissy trankDave fredricksonDamini chokshiEliav barrPeter dannenbaumProstate cancer working groupKeio university school of medicineEuropean unionJapanese ministry of healthMerck co incExchange commissionStatement of merck co incMerck research laboratories

Merck (MRK) Reports LYNPARZA Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Merck (MRK) Reports LYNPARZA Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEliav barrDave fredricksonPeter dannenbaumMototsugu oyaChrissy trankDamini chokshiJulie cunninghamStatement of merck co incMerck co incJapanese ministry of healthKeio university school of medicineExchange commissionEuropean unionMerck research laboratoriesProstate cancer working group

AstraZeneca: LYNPARZA (olaparib) and IMFINZI (durvalumab) combination reduced risk of disease progression or death by 37% vs chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial

Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA (olaparib), IMFINZI(durvalumab), chemotherapy and bevacizumab demonstrated

France generalUnited statesUnited kingdomBrendan mcevoyJessica mcduellSusan galbraithEuropean society of medical oncology congressNational cancer instituteWorld cancer research fund internationalIntj womens healthMerck co incAmerican society of clinical oncologyClinical oncologyAnnual meetingExecutive vice presidentAcute myeloid leukemia